特发性炎性肌病无糖皮质激素缓解后的复发率及IMACS完全临床缓解与恶化标准验证
研究从瑞典风湿病质量登记处提取494例特发性炎性肌病患者,其中159例(32%)达到医生判定的无糖皮质激素缓解,12年累积复发率为76%,抗Jo-1为危险因素。IMACS完全临床缓解标准各核心指标达标率从肌酸激酶23%至MMT8 95%不等,仅50%复发可被IMACS恶化定义捕获,需修订该标准。
要点
- 159/494例(32%)达到无糖皮质激素缓解,12年累积复发率76%,抗Jo-1为危险因素。
- 缓解后6个月内IMACS完全临床缓解达标率:肌酸激酶23%、HAQ 50%、患者总体评估70%、医生总体评估80%、肌外活动83%、MMT8 95%。
- 仅50%复发被IMACS恶化定义捕获,修订定义额外捕获15%,重新启用激素/免疫抑制剂捕获35%。
核心结论
- 特发性炎性肌病患者达到无糖皮质激素缓解后复发频繁,需要治疗管理,IMACS完全临床缓解/恶化标准需修订。
研究设计与样本
- 从瑞典风湿病质量登记处(SRQ)提取达到医生判定无糖皮质激素缓解的特发性炎性肌病患者,分析复发率及相关因素,并在缓解前后6个月内评估IMACS核心指标以评价完全临床缓解标准的表现。
主要发现
- 494例患者中159例(32%)达到医生判定的无糖皮质激素缓解,12年累积复发率为76%,抗Jo-1为危险因素。
- 从缓解时至缓解后6个月,IMACS完全临床缓解达标率:肌酸激酶23%、健康评估问卷50%、患者总体评估70%、医生总体评估80%、肌外活动83%、徒手肌力测试8项95%。
- 仅50%的复发可被IMACS恶化定义捕获,修订的IMACS恶化定义额外捕获15%的复发,重新启用糖皮质激素/免疫抑制剂治疗捕获35%的复发。
关键数值与推荐
- 复发定义为每次访视或从缓解至恶化时间点期间IMACS核心指标恶化超过20%至30%(修订定义)或启用糖皮质激素/免疫抑制剂。
- 从缓解至后续所有访视的变化进行比较,选择变化最大的访视作为恶化时间点(修订定义)。
临床怎么用
- 对于达到无糖皮质激素缓解的特发性炎性肌病患者,应关注复发风险,尤其是抗Jo-1阳性者。
- IMACS完全临床缓解标准中肌酸激酶达标率较低(23%),临床评估完全缓解时需注意各核心指标达标率不均。
- IMACS现行恶化定义可能低估复发,修订定义或重新启用治疗可补充捕获部分复发。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our aim was to explore maintenance of glucocorticoid-free remission in patients with idiopathic inflammatory myopathy (IIM). Additionally, we examined the performance of the International Myositis Assessment and Clinical Study Group (IMACS) criteria for complete clinical response and flare/worsening. METHODS: Patients achieving physician-determined glucocorticoid-free remission were extracted from the Swedish Rheumatology Quality Register (SRQ). Relapse rates and associated factors were analyzed. To assess the performance of complete clinical response criteria, IMACS core set measures were evaluated within six months before and after remission. Relapse was defined as IMACS criteria of worsening in IMACS core set measures over 20% to 30% during every visit or in the period from remission to a time point with worsening (modified definition) or glucocorticoid/immunosuppressant administration. Changes from remission to all subsequent visits were compared. The visit with the largest change was chosen as the worse time point (modified definition). RESULTS: Of 494 patients, 159 (32%) achieved physician-determined glucocorticoid-free remission. The 12-year cumulative relapse rate was 76%, with anti-Jo1 as a risk factor. From time of remission to six months after remission, IMACS complete clinical response fulfillment rates were as follows: creatine kinase, 23%; Health Assessment Questionnaire, 50%; patient global assessment, 70%; physician global assessment, 80%; extramuscular activity, 83%; and Manual Muscle Test 8, 95%. Only 50% of relapses could be captured by the IMACS worsening definition, but additional relapses were captured by a modified IMACS worsening definition (15%) or by reintroduction of glucocorticoid/immunosuppressant treatment (35%). CONCLUSION: Relapses were frequent in patients with IIM after achieving glucocorticoid-free remission and required management of therapy. IMACS criteria for complete clinical response/worsening need to be amended.
引用
- Tsuji H, Espinosa-Ortega F, Peralta Garcia I, et al. Relapse Rate After Glucocorticoid-Free Remission in Patients With Idiopathic Inflammatory Myopathies and Validation of the International Myositis Assessment and Clinical Studies Group Criteria for Complete Clinical Response and Worsening. Arthritis Rheumatol. 2026. PMID: 41211626. doi:10.1002/art.43429
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。